List of Antibodies Companies in North Carolina - 22

Adaptin Bio, is a pioneering biotechnology company dedicated to revolutionizing drug delivery. Our focus is on developing innovative technologies that enhance how medications and other therapeutic compounds reach their target destinations within the body. Our core mission is to overcome a major hurdle in medicine: ensuring effective delivery of drugs to specific tissues.

Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.

BA Sciences is a cGMP compliant, FDA/DEA registered, ISO/IEC-17025:2017 certified analytical laboratory located in Salem, NH. BA provides testing services to Pharmaceutical, Biopharmaceutical and Medical Device companies worldwide including: Analytical Testing and Method Development, Microbiological Testing and Environmental Monitoring Services, Biologics, Stability Testing & ICH-compliant Storage, Impurities Testing, Advanced Therapeutics and Extractables & Leachables Studies.

Bedrock Therapeutics is an AAV gene therapy research and development company developing platform and disease specific technologies for the treatment of ocular, hematologic, and other diseases. Drs. Matt Hirsch, Chenwen Li, Bryan Sutton, and Brian Gilger are co-founders of Bedrock. Drs. Gilger and Hirsch oversee the de novo design and validation of ocular assets, and Drs. Li and Sutton oversee basics aspects of the various host immune responses to AAV vectors and protein engineering and design.

Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's cloneXplorer and proprietary nanowell plates uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.

Clarus Biologics was launched to increase the availability of safe and effective prophylactic and therapeutic technologies. It’s lead product is a next-generation vaccine Virus Like Particle intended to enhance the effectiveness, efficiency and availability of vaccines.Clarus Biologics is Dedicated to the Discovery and Development of Novel Vaccine and Immunology Technologies

Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. Our technologies and products are making studies possible that were not imaginable just a few years ago. Our renowned chromatin researchers possess expertise and unique insight into chromatin biology and drug discovery that benefit our customers in ways other companies cannot. Epigenetics, the study of changes in heritable traits that occur independent of alterations in changes in the underlying DNA sequence, is an emerging and important area of biomedical research with broad impact on human health and disease.

At GeneVentiv, we’re blazing a trail. We’re driven by curiosity. We’re fueled by learning expressed as innovation. Our mission is to discover, develop and deliver gene therapies for patients who had no hope of a cure – until now. We are founded on discovery bringing together insights into Adeno Associated Virus (AAV) directed gene therapy, Hemophilia and how to use the common pathway in the clotting cascade to surmount the obstacle of inhibitors. Patients with inhibitors are unable to respond to current therapies and gene therapies in development due to neutralizing antibodies (inhibitors) formed by the body in response to treatment with missing clotting factor. Our goal is to cure inhibitor patients with a single lifetime infusion, not to offer a half measure of weekly injections of a bypass agent.

Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. The antibody was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103”, the company’s lead asset, is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients.

We are your worldwide manufacturer of quality polyclonal antibodies used in research and in vitro diagnostics. We have a wide range of secondary antibodies covering a broad spectrum of immunoglobulins from various species and cross absorbed to provide high specificity. We are also your source for primary polyclonal antibodies to hormones, cancer markers, cardiac markers and serum proteins. In addition to our product lines, we offer custom absorptons and purifications to meet specific requirements, yet knowledgeable and experienced to provide bulk manufacturing within cGMP guidelines and ISO quality systems requirements.

Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications and sometimes death.

Isolere's mission is to increase global access to life-changing therapeutics and vaccines by offering novel purification reagents to alleviate manufacturing bottlenecks. The IsoTag™ reagents reimagine bioprocessing by combining target specific affinity ligands with phase separating biopolymers. The Affinity Liquid Phase Separation (ALPS) allows target biologics to be separated on the basis of affinity and size in a single process and can be implemented in a variety of techniques including microfiltration TFF and centrifugation processes. Isolere is currently developing purification solutions for adeno-associated virus (AAV), lentivirus (LV), adenovirus (AdV) and mRNA. Visit our website to learn more! Isolere Bio was acquired by Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, in February 2023.

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.

KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 500+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. KBI is proud to be a JSR Life Sciences Company.

LigaTrap has developeda patented portfolio of affinity ligands that can be used to purifymonoclonal and polyclonal immunoglobulins from various species.

First in-class platform for harnessing the synergy between antibodies and mucus to reinforce the mucus barrier for mucosal health Proprietary intravaginal ring technologies for sustained delivery of small molecules to biomacromolecules Unparalleled safety from topical delivery

Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate significantly higher than the industry average. NovaQuest is actively evaluating and investing into global opportunities with financing needs that range from $30-100 million. For more information, please visit www.novaquest.com

OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company has just launched its first product: Agkura™ Personal Score – a simple, non-invasive blood test that aids breast cancer detection in women with dense breast tissue. Roughly half of the women in the US have dense breast tissue and mammograms miss 50% of the breast cancers in these women, resulting in late stage diagnosis and mortality. Agkura™ Personal Score measures the biomarker tumor-associated MUC1 (tMUC1) and shows a trend of increasing value from benign disease through breast cancer stages 1 to 4. Women can monitor their personal score in conjunction with annual mammograms. A score above the normal range or an increase greater than normal variation will trigger a recommendation for diagnostic imaging (ultrasound or MRI), resulting in earlier stage diagnosis of breast cancer. The company is also working on developing treatments for breast and pancreatic cancers.

Monoclonal Antibody

Villaris Therapeutics is a preclinical-stage biopharmaceutical company focused on developing novel antibody therapeutics for the treatment of vitiligo. A recent discovery revealed that an immune pathway, initiated by IL-15 signaling and its formation of autoimmune memory T cells (TRM), was responsible for the return of vitiligo usually soon after stopping treatments. Targeting this pathway therapeutically was very effective at reversing the disease in a mouse model of vitiligo with long-lasting results. Villaris Therapeutics is developing a novel humanized anti-IL-15R antibody to target depletion of TRM for the effective and durable treatment of vitiligo and other tissue-specific autoimmune diseases that also involve these cells.